Capecitabine Plus Temozolomide (CAP-TEM) in Patients with Advanced Neuroendocrine Tumors (NETs): An Italian Multicenter Retrospective Analysis

Francesca Spada1; Caterina Fumagalli2; Eleonora Pisa2; Lorenzo Antonuzzo2; Luca Messerini4; Davide Radice5; Roberta Di Rocco1; Salvatore Galdy1; Viola Barucca6; Massimo Barberis2; Francesco Di Costanzo3; and Nicola Fazio1

1GI and NET Unit, European Institute of Oncology, Via Ripamonti 435, 20141, Milano, Italy
2Histopathology and Molecular Diagnostics Unit, European Institute of Oncology, Via Ripamonti 435, 20141, Milano, Italy
3Medical Oncology 1, AOU Careggi, Viale Pieraccini 17, 50139, Firenze, Italy
4Experimental and Clinic Department, AOU Careggi, Largo Brambilla, 3, 50134 Firenze, Italy
5Biostatistics and Epidemiology Department, European Institute of Oncology, Via Ripamonti 435, 20141, Milano, Italy
6Medical Oncology AOU,"Sapienza" University „Sant'Andrea Hospital, Via di Grottarossa 1035, 00189, Roma, Italy

Background: A combination of capecitabine (CAP) and temozolomide (TEM) has been successfully used as first-line treatment in low-grade pancreatic neuroendocrine tumors (pNETs). We reviewed activity and toxicity of the same regimen in patients with advanced NETs with different primary and grading.

Methods: Clinical data of patients who had received oral CAP 1500 mg/m2/day over 14 days bid plus oral TEM 150-200 mg/m2/day on days 10-14 of each 28-day cycle, were retrospectively reviewed. The methylguanilimetiltransferase (MGMT) methylation-status (MGMT-gene >5% = responders) and TS-polymorphisms (2R/2R, 2R/3R = responders, 3R/3R = non-responders) in tumor-tissue/peripheral-blood were evaluated by pyrosequencing.

Results: Since March 2012, 26 patients were selected. The primary tumor was: pancreas in 13 patients (50%), gastrointestinal (GI) in 3 (11%), unknown in 2 (8%), lung in 8 (31%). According to 2010 WHO classification, Ki67 was 3-20% (G2) in 42% patients, >20% (G3) in 23% with two "low G3" (Ki67 21-30%), and unknown in 4%. Among lung: 8% typical and 23% atypical (Travis’ classification). 73% patients (19/26) were progressive on different therapies: peptide-receptor-radiotherapy (58%), everolimus (26%). Partial-response (PR) occurred in 15% (4/26) of patients (95% CI: 4-35), stable-disease (SD) in 65% (17/26) (95% CI: 44-83) mainly pNET. The two "low G3" responded. Disease control rate (PR+SD): 80% (95% CI: 60-93). Median TTP: 8 months (95% CI: 0.46-N.E.). Thrombocytopenia was the most frequent grade 3 toxicity, always temporary. All 4 PR patients had genotype 2R/2R-2R/2R investigated for the 28 base-pair (bp) variable number of tandem repeats (VNTR) in the 5'UTR of the TS-gene, and MGMT-gene inactivation by epigenetic silencing.

Conclusions: This analysis suggests that CAP-TEM chemotherapy could be active and well tolerated in pre-treated patients with advanced NETs of different origins and grading. This warrants a prospective investigation in a more homogeneous population (G2 and “low-G3” GEP NETs or lung carcinoids), in order to validate the predictive value of MGMT methylation-status and TS-polymorphisms.